JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

Search

Arbutus Biopharma Corp

Closed

3.34 2.14

Overview

Share price change

24h

Current

Min

3.24

Max

3.35

Key metrics

By Trading Economics

Income

-12M

-25M

Sales

190K

1.8M

Profit margin

-1,390.363

Employees

44

EBITDA

-12M

-24M

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

158K

642M

Previous open

1.2

Previous close

3.34

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Arbutus Biopharma Corp Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 Aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 Aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 Aug 2025, 21:30 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 21:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 Aug 2025, 21:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss $938M >RIG

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss/Shr $1.06 >RIG

4 Aug 2025, 20:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:09 UTC

Earnings

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 Aug 2025, 20:06 UTC

Earnings

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 Aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 Aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 Aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 Aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.